Thursday, October 4, 2012

Astellas presents new data on its SGLT2 inhibitor - Ipragliflozin

Astellas presented new data  from two Phase 3 studies in Japanese patients. In one of the double blind placebo controlled studies Ipragliflozin in combination with Sulfonylurea was explored in 242 patients. After 24 weeks, Ipragliflozin could cut HbA1C by 1.14% compared to placebo (sulfonylurea alone). In another study in combination
with Pioglitazone, Ipragliflozin reduced HBA1C by 0.88% compared to placebo (pioglitazone alone). In the SU study, Ipragliflozin reduced weight by 1.32 kg, while in the pio study, Ipragliflozin cut weight by 2.8kg.

The incidences of hypoglycaemia, genital infections, and urinary tract infections with IPRA occurred in 1.2%, 0.6%, and 1.2% of patients in the SU study, respectively, and 1.0%, 2.1%, and 3.1% in the PIO study, respectively; the incidences in the placebo arm were respectively 1.3%, 3.9%, and 3.9% in the SU study and 0.0%, 0.0%, and 1.9% in the PIO study, respectively.